Africa Races for Ebola Vaccine as Outbreak Outpaces Response

• Researchers are accelerating vaccine development for the Bundibugyo Ebola virus, which is currently spreading in the Democratic Republic of Congo (DRC).
• The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged US$62 million to fast-track three investigational vaccine candidates.
• International agencies and the Africa CDC are coordinating efforts to scale up production and manage a regional response.

Vaccine Development Timeline

• The Oxford University vaccine candidate aims to have clinical-grade doses ready for human testing within two to three months.
• The IAVI rVSV single-dose candidate, identified by WHO as a top priority, is projected to be ready for human trials in seven to nine months.
• Technical teams are evaluating whether a Russian-developed vaccine platform targeting the Zaire strain can be adapted for the Bundibugyo virus.

Outbreak and Regional Impact

• As of May 29, 223 deaths were suspected in the DRC, with 15 confirmed cases in Uganda.
• The Africa CDC identified 11 high-risk neighboring countries—including South Sudan, Rwanda, and Kenya—vulnerable due to cross-border movement.
• The African Union seeks US$319 million over the next six months to implement a continent-wide control plan.
• Gavi, the Vaccine Alliance, has committed US$50 million to facilitate immediate response and future manufacturing readiness.

Experimental Therapeutics

• The WHO is evaluating multiple experimental therapies, including monoclonal antibodies (MBP134, Maftivimab) and antivirals (remdesivir).
• Researchers are studying obeldesivir tablets as a potential post-exposure prophylactic to prevent infection in confirmed contacts before symptom onset.